Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain

  1. Irimia, P.
  2. Santos-Lasaosa, S.
  3. García Bujalance, L.
  4. Ramos Pinazo, L.
  5. Rubio-Rodríguez, D.
  6. Rubio-Terrés, C.
Journal:
Expert Review of Pharmacoeconomics and Outcomes Research

ISSN: 1744-8379,  1473-7167

Year of publication: 2021

Volume: 21

Issue: 2

Pages: 285-297

Type: Article

DOI: 10.1080/14737167.2020.1768850 GOOGLE SCHOLAR

Sustainable development goals

Data source: Scopus